[nanoPost] Anoemulsion technology for topical, transdermal and intranasal drug delivery

Company Israel

The company's scientists have developed a novel, proprietary, versatile and biocompatible nanoemulsion technology for topical, transdermal and intranasal drug delivery (patent pending). It offers complete incorporation and solubility of large amounts of almost any lipophilic and hydrophilic compound as well as large molecules (e.g. peptides and proteins).

The non-injectable insulin market is now facing a renaissance. The company has therefore set to develop a novel intranasal insulin delivery formulation. The feasibility is demonstrated in a series of pharmacokinetics (PK) and pharmacodynamics (PD) studies carried out in rabbits with Alloxan-induced diabetes, in comparison with IV and SC insulin administrations.